|
Incomplete Autophagy Induction for the Treatment of Cancer
SHORT DESCRIPTION
This incomplete autophagy inducer triggers caspase-mediated apoptosis in cancer cells by inducing incomplete autophagy, leading to tumor reduction and improved survival.
INVENTORS
INVENTORS
Maciej Lesniak*
Northwestern University Feinberg School of Medicine, Department of Neurological Surgery
Jawad...
Published: 5/13/2026
|
Updated: 5/7/2026
|
Inventor(s):
Keywords(s): Autophagy, Brain cancer, Breast cancer, Cancer/Oncology, Lung cancer, Melanoma, Repurposed Drugs, Small molecule, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Anti-TYRP1 Bi-specific T cell Engager for Treatment of TYRP1-expressing melanoma
NU 2022-123
INVENTORS
Irina Balyasnikova (Feinberg School of Medicine, Department of Neurological Surgery)*
Isabelle Le Poole (Feinberg School of Medicine, Department of Dermatology)*
SHORT DESCRIPTION
A bispecific T cell engager that targets CD3+ T cells and TYRP1-expressing melanoma cells.
BACKGROUND
Melanoma is the deadliest form of skin...
Published: 4/14/2026
|
Updated: 4/14/2026
|
Inventor(s):
Keywords(s): Biologic, Cancer/Oncology, Immunotherapy, Melanoma, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and neurodegenerative disorders
NU 2025-113 (NU 2016-137, NU 2018-176, NU 2019-179, NU 2023-007, NU 2024-250, NU 2025-038)
INVENTORS
Richard Silverman
Weinberg College of Arts and Sciences, Department of Chemistry
SHORT DESCRIPTION
Novel highly selective neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and other cancers with high expression...
Published: 5/21/2026
|
Updated: 4/1/2026
|
Inventor(s):
Keywords(s): ALS - Amyotrophic Lateral Sclerosis, AUTM26C1, BIAUTM1, Cancer/Oncology, Cardiology and Cardiovascular disease, Immunodeficiency, Immunology, Immunotherapy, Melanoma, Neurodegenerative disease, Neuroinflammation, nNOS, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Covalent PRC2 Inhibitors for Advanced Cancer Therapeutics
SHORT DESCRIPTION
Covalent inhibitors and proteolysis-targeting chimera (PROTAC) degraders targeting components of the PRC2 complex (EZH and EED) to block both enzymatic and non-enzymatic functions, offering robust anti-tumor efficacy.
INVENTORS
Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)*
Jindan...
Published: 5/6/2026
|
Updated: 3/5/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Bladder cancer, Breast cancer, Cancer/Oncology, Covalent inhibitor, Lymphoma, Melanoma, PreSeed/Seed, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|